| Name | Title | Contact Details |
|---|---|---|
Jerome Maddox |
Vice President and Associate General Counsel, Commercial Legal and Public Policy | Profile |
Neal Dahiya |
Senior Vice President and Head of Litigation | Profile |
Lisa Kinsella |
Associate General Counsel | Profile |
Jacob Moore |
Intellectual Property Counsel | Profile |
Megan Williams |
VP, Associate General Counsel, Intellectual Property | Profile |
InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.
Formerly known as the new center for advanced biological innovation and manufacturing (or “CABIM”), Landmark Bio, PBLLC is a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today`s cutting-edge research into tomorrow`s breakthrough therapies. The cross-sector partnership harnesses world-leading expertise to accelerate fast-emerging and promising science, the challenges of which are daunting for any single institution to tackle alone. Board members include leaders from Harvard University, Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children`s Hospital, Brigham and Women`s Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Massachusetts Life Sciences Center.
Patara Pharma is a biopharmaceutical company developing a new therapy for the treatment of allergic and immunologic diseases and conditions that affect orphan patient populations. We completed a Phase 1 clinical trial with favorable results and have initiated Phase 2 clinical trials for several undisclosed indications that will read-out by the end of 2015.
New Economy Strategies is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Roche NimbleGen is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.